CClinicalTrials.gg
WithdrawnNCT02516020Updated Apr 18, 2017

Effectiveness of Single Step Culture Media and Sequential Culture Media on Blastulation Rate

An interventional study of Global and Origio in Infertility, sponsored by Vietnam National University. Withdrawn at 1 site in Vietnam. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Vietnam National University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

To compare the effectiveness of single step culture media and continuous uninterrupted culture media on blastulation rate

Read the detailed description

Sequential culture media are designed to mimic the changing environment in the ovary ducts and the uterus in vivo. However, there are some differences between in vivo and in vitro culture conditions. Hence, single step media are created which allow the embryo itself to choose the necessary nutrients while maintaining a more stable culture environment. Previous studies suggest higher blastulation rate in the single step media than the sequential media.

This is an Randomized controlled trial (RCT) study comparing the blastulation rate of single step culture media and sequential culture media. Stimulation protocol is antagonist. Patient will be consulted on the day of ultrasound if they meet the inclusion criteria and sign the consent form. Then, the nurse will open the letter containing the type of media for that case. The media is prepared inside the lab a day before oocyte pick-up.

After oocyte pick-up, the oocyte-cumulus complex (OCC) will be cultured for 2 hours at 37°C, 6% Carbon dioxide (CO2) and 5% oxygen (O2). Meanwhile, sperm preparation will be performed using gradient technique. After 2 hours, OCC will be denuded and will be cultured for 1 hour until Intracytoplasmic Sperm Injection (ICSI). Oocytes after ICSI will be cultured in groups of 3-4 oocytes in the same conditions of 37 ° C, 6% CO2 and 5% O2. Fertilization check procedure is at 16-18 hours after ICSI. On day 3, the embryos will be evaluated in 66-68 hours after ICSI, grade 1 embryos are identified with 7-9 blastomeres and fragmentation is from 0-10%. The patients will be informed about the embryo quality. If the embryos are not decided to have day 5 transferring, patient will be consulted to transfer on day 3. Blastulation rate will not be recorded.

For the sequential culture media group, embryos will be transferred to Sequential Blast medium. For the single step culture media group, embryos will be transferred to the new culture dish with the same medium. On day 5, embryo quality assessment will be at 116±1 hours after ICSI. Blastocyst grading is based on the expansion, inner cell mass quality, and trophectoderm quality. Two good blastocyst will be transferred. After 11 days, beta-human chorionic gonadotropin (hCG) test will be required. If the beta-hCG result is positive, examination will be needed after 3 weeks and the luteal support will be given until 7 weeks.

02

Conditions studied

  • Infertility

Browse trials for

Keywords

  • IVF
  • ICSI
  • culture media
  • sequential
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

Browse Infertility studies →

Lead sponsor

Vietnam National University is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Number of previous failure IVF cycles ≤2
  • Using Gonadotropin-releasing hormone (GnRH) - Antagonist protocol for IVF
  • Using GnRH for oocyte triggering.
  • Read and sign consent form to participate in the study and have not been recruited for any other researches.

Exclusion criteria

Exclusion Criteria:

  • Oocyte donation cycles
  • Abnormal uterine.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Global

    EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)

    Drug: Global

  • Active comparator
    Origio

    Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)

    Drug: Origio

Interventions

  • DrugGlobal

    Embryos are cultured in single step culture from day 1 to day 5

    Also known as: Global medium (LifeGlobal)

  • DrugOrigio

    Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)

    Also known as: Sequential Blast (Origio)

06

What researchers measure

Primary outcomes

  1. The blastulation rate

    The blastulation rate is defined as the number of blastocysts from 2 pronuclei (2PN) zygotes

    Time frame: 116 ±1 hours after ICSI

Secondary outcomes

  1. Implantation rate

    Implantation rate is defined as the number of gestational sacs per number of embryos transferred.

    Time frame: 11 days after embryo transfer

  2. Clinical pregnancy

    Clinical pregnancy is defined by the image gestational sac under ultrasonography.

    Time frame: 7 weeks after embryo transfer

07

Study locations

1 site
  • My Duc Hospital
    Ho Chi Minh, Vietnam
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02516020
Lead sponsor
Vietnam National University
Collaborators
Mỹ Đức Hospital
Responsible party
Manh Tuong Ho (Doctor, Vietnam National University) — Principal investigator
First posted
Aug 5, 2015
Start date
Aug 2015
Primary completion
Aug 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Apr 18, 2017

Study contacts

Tuong M Ho, MD
principal investigator · Research Center for Genetics and Reproductive Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion